KeyBank National Association
AERI

KeyBank National Association’s Aerie Pharmaceuticals AERI Stock Holding History

KeyBank National Association’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-8,480
Closed -$210K – 1292
2014
Q2 		$210K Buy
+8,480
New +$147K ﹤0.01% 1201
2014
Q1 		– Sell
-11,308
Closed -$203K – 1303
2013
Q4 		$203K Buy
+11,308
New +$147K ﹤0.01% 1198

Other funds holding AERI

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

KeyBank National Association's AERI Position: Q3 2014 in Review

KeyBank National Association sold out of Aerie Pharmaceuticals (AERI) in Q3 2014, closing a stake of 8,480 shares — an estimated $210K sold.

KeyBank National Association first reported a position in AERI in Q4 2013 and held it in 2 quarters. The position peaked at $210K in Q2 2014. 76 funds tracked by Wall St. Rank hold AERI as of Q3 2014.

  • KeyBank National Association reported no remaining Aerie Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • KeyBank National Association sold 8,480 Aerie Pharmaceuticals shares in Q3 2014, an estimated $210K.
  • KeyBank National Association first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • KeyBank National Association's Aerie Pharmaceuticals position peaked at $210K in Q2 2014.
  • 76 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2014.

Based on KeyBank National Association's 13F filing for Q3 2014, filed 7 Nov 2014.